InterMune (NASDAQ:ITMN) VP Sean Nolan sold 2,644 shares of InterMune stock in a transaction dated Thursday, May 8th. The stock was sold at an average price of $35.85, for a total value of $94,787.40. Following the completion of the sale, the vice president now directly owns 72,556 shares of the company’s stock, valued at approximately $2,601,133. InterMune Inc. (NASDAQ:ITMN) weekly performance is -4.88%. On last trading day company shares ended up $34.31. Analysts mean target price for the company is $39.50. InterMune Inc. (NASDAQ:ITMN) distance from 50-day simple moving average (SMA50) is 6.53%.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) shares fell -3.25% in last trading session and ended the day on $24.70. ISIS gross Margin is -24.90% and its return on assets is -8.10%.ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) quarterly performance is -52.65%.
NPS Pharmaceuticals (NASDAQ:NPSP) reported first-quarter net sales of Gattex totalling $17.9 million, a consensus miss which the company blames on bad winter weather and a rise in the number of patients discontinuing therapy. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) shares moved down -3.27% in last trading session and was closed at $26.04, while trading in range of $25.39 – $26.92. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) year to date (YTD) performance is -14.23%.
Incyte Corporation (NASDAQ:INCY) inked a deal with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The companies have collaborated for a phase I/II study to evaluate the efficacy and safety of AstraZeneca’s MEDI4736 in combination with Incyte’s INCB24360 in cancer patients. Incyte Corporation (NASDAQ:INCY) ended the last trading day at $49.59. Company weekly volatility is calculated as 5.83% and price to cash ratio as 16.01.Incyte Corporation (NASDAQ:INCY) showed a negative weekly performance of -4.78%.
Seattle Genetics Inc. (NASDAQ:SGEN) announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting being held May 30 to June 3 2014 in Chicago IL. Seattle Genetics, Inc. (NASDAQ:SGEN) net profit margin is -22.30% and weekly performance is -3.11%. On last trading day company shares ended up $34.25. Analysts mean target price for the company is $45.15. Seattle Genetics, Inc. (NASDAQ:SGEN) distance from 50-day simple moving average (SMA50) is -19.29%.
Leave a Reply